Motif Bio Share Discussion Threads

[ianb5004] 15/11/2017 08:14

Tim if you genuinely think that then your completely clueless and should not invest in aim. This is everything a death spirall isnt.

This is excellent news loan secured against assets, shows the lenders faith in Iclaprims likely sucess. This also now gives motif the strongest hand when negitiating Licencing deals with Rest of world partners.

Anyone who seeks to spread negatives is either out wanting in or has a short.

[dave4545] 15/11/2017 08:13

You have to filter timw3 it is the only way.

He is just scum

[drmaccers] 15/11/2017 08:10

Looks like Tim has no idea what he's talking about

[tilly99] 15/11/2017 08:06

Death spiralling?There is no issue of shares apart from warrantsTim are you a massive buyer desperate for a good entry as your posts are v odd

[1savvyinvestor] 15/11/2017 08:05

Timw3. This is not death spiral finance. Hercules capital are specialists in debt finance for pharma companies. They have released 15 million immediately. That is not how death spiral companies work. They release small amounts at regular intervals shorting into the lending. This is totally different.

[timw3] 15/11/2017 08:01

dead cat boubce followed by a fall back as they realise this is most likely death spiralling

[pugugly] 15/11/2017 07:58

timw3_ Could be a problem if timelines slip substantially but not the usual "death spiral" of unlimited issue of shares at significant discount and then sold inot themarket driving share price down. (imo)

[mirabeau] 15/11/2017 07:55

Photon

Good spot

thanks T90 - I thought so

[timw3] 15/11/2017 07:54

Oh dear... Looks like death spiralling

[1savvyinvestor] 15/11/2017 07:52

From my reading this looks good. I always look at debt finance for something dodgy but looks like Hercules Capital are genuine experts in the field. There is a very clear time scale here and motif are taking £15 million immediately as 2018 is THE massive year for them. Should mean the so recovers from here but being AIM. Who knows?!

[photon] 15/11/2017 07:41

Reasonable to conjecture that Merrill Lynch will have made the Hercules introduction. Hercules Tech MD Tom Harris is ex-Merrill. Merrill have recently bought a big stake in Motif, as we know.

[tilly99] 15/11/2017 07:36

It's tiny dilution as 1.5m shares Let's hope we can repay the loan or will lose most of our assets!! LolSector been weak but this stops holders selling in hope of some cheap equity 40p on the open and a rebound back to the highs of 52p over the next few weeks IMHO

[dave4545] 15/11/2017 07:35

pyglet

timw3 will probably spam half this site with MTFB 100-200p posts once he has bought
back in this morning.

Advfn are useless for not moderating twerps like him.

[mirabeau] 15/11/2017 07:29

Yes, no equity dilution. Does the warrant issued to Hercules involve slight dilution or am I reading that wrong? Small brain, can't work it out. Either way it provides a huge degree of leeway for the company to secure conditional commercial agreements for Iclaprim

I like the fact that Hercules is a specialist pharma financing entity so it's understanding of risk with companies like Motif will be top notch. It must be confident that Motif will secure FDA approval for Iclaprim

A huge vote of confidence in both the company and Iclaprim

[tilly99] 15/11/2017 07:25

Must be over 40p today

[pyglet] 15/11/2017 07:25

Back to 40p now??

[pyglet] 15/11/2017 07:24

As I said Timw3 - dreamland

[tilly99] 15/11/2017 07:19

No equity dilution Should motor on this

[adorling] 15/11/2017 07:15

Reassuring to know we are now funded through to licences and commercialisation.

[metis20] 15/11/2017 07:10

From today's RNS

"London and New York, Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has entered into an agreement for up to US$20 million in debt financing with Hercules Capital, Inc. (NYSE: HTGC), a leader in customised debt financing for companies in life sciences and technology-related markets. The funds will be used to fund pre-commercialisation activities and other corporate activities in preparation for the anticipated US launch of iclaprim in 2019."

[timw3] 13/11/2017 16:33

really? lets see.

[pyglet] 13/11/2017 16:32

timv - you are in dreamland my friend.

[1savvyinvestor] 13/11/2017 16:20

No way tim!